ReviewCancer medicine2022
Challenges posed by COVID-19 in cancer patients: A narrative review.
Review in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.Journal of clinical laboratory analysis · 2022Pooled it
- A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials.Acta haematologica · 2022Pooled it
- COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety.Frontiers in endocrinology · 2022Pooled it
- Proton Therapy Patient Selection Methods and the Impact of COVID-19: A Cross-Sectional International Survey.Journal of medical radiation sciences · 2025Article
- Youths Experiencing Parental Death Due to Cancer.JAMA network open · 2025Article
- Propensity score matching analysis of perioperative outcomes during Hub&Spoke training program in hepato-biliary surgery.Scientific reports · 2025Article
- Sex-Disaggregated Analysis of Central Venous Catheter-Related Bloodstream Infections in Patients with Cancer.Oncology research and treatment · 2025Article
- Decoding prognostic factors in SARS-CoV-2 complications among patients with hematological disorders.Clinics (Sao Paulo, Brazil) · 2025Article
- Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma.International journal of hematology · 2024Article
- Proton radiation therapy patient selection and impacts of COVID-19: A scoping review.Journal of medical radiation sciences · 2024Article
- Article
- Article
- The Impact COVID-19 Infection on Cancer Patients: A Tertiary Cancer Center Experience in Jordan.Cureus · 2023Article
- The impact of the COVID-19 pandemic on the diagnosis and treatment of skin cancers, a mini review.Cancer reports (Hoboken, N.J.) · 2023Review
- COVID-19 andInfectious disease reports · 2023Article
- Application of cell-derived exosomes in the hematological malignancies therapy.Frontiers in pharmacology · 2023Review
- Assessing eHealth Literacy and Identifying Factors Influencing Its Adoption Among Cancer Inpatients: A Cross-Sectional Study in Guangdong Population.Patient preference and adherence · 2023Article
- COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.Journal of cosmetic dermatology · 2022Review
- Preclinical Assessment of Immunogenicity and Protectivity of Novel ROR1 Fusion Proteins in a Mouse Tumor Model.Cancers · 2022Article
- How did SARS-CoV-2 changed the landscape in cancer care.European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the causative agent of coronavirus disease 2019 (COVID-19). In early 2020, the World Health Organization declared COVID-19 the sixth public health emergency of international concern. The COVID-19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID-19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID-19. However, cancer patients' risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID-19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.